Literature DB >> 15986939

West Nile virus. Primer for family physicians.

Russell D MacDonald1, Valerie F Krym.   

Abstract

OBJECTIVE: To provide primary care physicians with an understanding of West Nile virus in North America. This article focuses on epidemiology, clinical features, diagnosis, and prevention of infection. QUALITY OF EVIDENCE: MEDLINE and EMBASE searches revealed epidemiologic, surveillance, cohort, and outcome studies providing level II evidence. There were no randomized controlled trials of treatment. Recommended prevention and treatment strategies are based on level II and III evidence. MAIN MESSAGE: The mosquito-borne virus that first appeared on this continent in 1999 is now prevalent throughout North America. Most infections are asymptomatic. Fewer than 1% of those infected develop severe illness; 3% to 15% of those with severe illness die. While methods for controlling the mosquito population are available, we lack evidence that they reduce infection in the general human population. Family physicians have an important role in advising their patients on ways to prevent infection and in identifying patients who might be infected with West Nile virus.
CONCLUSION: The general population is at low risk of West Nile virus infection. Prevention of infection rests on controlling the mosquito population and educating people on how to protect themselves against mosquito bites.

Entities:  

Mesh:

Year:  2005        PMID: 15986939      PMCID: PMC1479528     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  26 in total

1.  Human surveillance for West Nile virus infection in Ontario in 2000.

Authors:  E Lee Ford-Jones; Margaret Fearon; Chuck Leber; Prabo Dwight; Moira Myszak; Beverly Cole; Pam Baker Greene; Sheila Artes; Allison McGeer; Colin D'Cunha; Monika Naus
Journal:  CMAJ       Date:  2002-01-08       Impact factor: 8.262

2.  Use of immunoglobulin m cross-reactions in differential diagnosis of human flaviviral encephalitis infections in the United States.

Authors:  Denise A Martin; Brad J Biggerstaff; Becky Allen; Alison J Johnson; Robert S Lanciotti; John T Roehrig
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

3.  Potential North American vectors of West Nile virus.

Authors:  M J Turell; M R Sardelis; D J Dohm; M L O'Guinn
Journal:  Ann N Y Acad Sci       Date:  2001-12       Impact factor: 5.691

Review 4.  West Nile virus.

Authors:  Grant L Campbell; Anthony A Marfin; Robert S Lanciotti; Duane J Gubler
Journal:  Lancet Infect Dis       Date:  2002-09       Impact factor: 25.071

5.  Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro.

Authors:  John F Anderson; James J Rahal
Journal:  Emerg Infect Dis       Date:  2002-01       Impact factor: 6.883

6.  Short report: absence of protective neutralizng antibodies to West Nile virus in subjects following vaccination with Japanese encephalitis or dengue vaccines.

Authors:  N Kanesa-Thasan; J R Putnak; J A Mangiafico; J E Saluzzo; G V Ludwig
Journal:  Am J Trop Med Hyg       Date:  2002-02       Impact factor: 2.345

7.  Human Exposures to N,N-diethyl-m-toluamide insect repellents reported to the American Association of Poison Control Centers 1993-1997.

Authors:  John W Bell; Joseph C Veltri; Brent C Page
Journal:  Int J Toxicol       Date:  2002 Sep-Oct       Impact factor: 2.032

8.  Clinical findings of West Nile virus infection in hospitalized patients, New York and New Jersey, 2000.

Authors:  D Weiss; D Carr; J Kellachan; C Tan; M Phillips; E Bresnitz; M Layton
Journal:  Emerg Infect Dis       Date:  2001 Jul-Aug       Impact factor: 6.883

9.  Dead crow densities and human cases of West Nile virus, New York State, 2000.

Authors:  M Eidson; J Miller; L Kramer; B Cherry; Y Hagiwara
Journal:  Emerg Infect Dis       Date:  2001 Jul-Aug       Impact factor: 6.883

Review 10.  Yellow fever vector live-virus vaccines: West Nile virus vaccine development.

Authors:  J Arroyo; C A Miller; J Catalan; T P Monath
Journal:  Trends Mol Med       Date:  2001-08       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.